Seidel C, Reinalter S, Seyberth H W, Schärer K
University Children's Hospital, Heidelberg, Germany.
Pediatr Nephrol. 1995 Dec;9(6):723-8. doi: 10.1007/BF00868723.
Pre-pubertal body growth was followed in eight children with the hyperprostaglandin E syndrome (neonatal Bartter syndrome) treated with indomethacin over a period of 5-12 years. When corrected for prematurity, the general growth pattern was normal, with the exception of a child with delayed therapy. From the first observation (usually at birth) to the start of indomethacin, the mean height standard deviation score (SDS) corrected for prematurity changed from -0.2 to -2.8. During the first 2 years of therapy rapid catch-up growth occurred, followed by a slow adaptation of the growth pattern to that of healthy children born at term. At last observation the mean corrected height SDS was -0.5 (range -1.9 to +0.9) and the mean target height -0.9 SDS (range -1.8 to +0.1). Weight, body mass index and bone maturation also reached the normal range. No correlation was found between height SDS per year and serum potassium levels or calcium excretion. We conclude that under indomethacin treatment long-term skeletal growth of children with the hyperprostaglandin E syndrome is similar to that of other preterm children.
对8例接受吲哚美辛治疗5至12年的高前列腺素E综合征（新生儿巴特综合征）患儿青春期前的身体生长情况进行了跟踪观察。校正早产因素后，除1例治疗延迟的患儿外，总体生长模式正常。从首次观察（通常在出生时）到开始使用吲哚美辛，校正早产因素后的平均身高标准差评分（SDS）从-0.2变为-2.8。在治疗的前2年出现快速追赶生长，随后生长模式缓慢适应足月出生的健康儿童。在最后一次观察时，校正后的平均身高SDS为-0.5（范围为-1.9至+0.9），平均目标身高SDS为-0.9（范围为-1.8至+0.1）。体重、体重指数和骨骼成熟度也达到正常范围。未发现每年的身高SDS与血清钾水平或钙排泄之间存在相关性。我们得出结论，在吲哚美辛治疗下，高前列腺素E综合征患儿的长期骨骼生长与其他早产儿童相似。
